Recently, Shanghai Henlius Biotech, Inc。 has completed data analysis of the Phase 1 study for its HLX03 (Recombinant Anti-TNFα Human Monoclonal Antibody Injection, a proposed adalimumab biosimilar)。 In December 2015 and April 2017, HLX03 was accepted by t
We shall continue to execute on our strategy of China for Global by supplying high quality and affordable biopharmaceutical products worldwide。Dr。 Scott Liu, Co-founder, President and CEO of HenliusShanghai Henlius Biotech, Inc。, was co-founded by Fosun P
Henlius has recently received an investigational new drug (IND) application acceptance notification from the National Medical Products Administration (NMPA) for its HLX22, a monoclonal antibody injection, for the treatment of gastric cancer (GC) and breas
From the screening of cell lines to cell culture development, Henlius professional team make effort in maximizing output, while ensuring high quality of products. Our international standard laboratory is equipped with advanced equipment, and we make use of our abundant technical and scientific expertise to develop and optimize the production process...
In Henlius, employees are of overriding importance and talents are the most valuable assets for the company。 We recognize talents and make the best of them through cultivation with professional trainings to retain them。。。。。。